# Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer

> **NCT05917860** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Turku University Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Localized Prostate Carcinoma
- Castration-Naive Prostate Cancer
- Intermediate Risk Prostate Cancer
- Prostate Cancer

## Interventions

- **DRUG:** Degarelix
- **DEVICE:** MRI-guided transurethral ultrasound ablation (TULSA)

## Key facts

- **NCT ID:** NCT05917860
- **Lead sponsor:** Turku University Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-18
- **Primary completion:** 2026-01-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05917860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05917860, "Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05917860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*